FindTrial
Sign In

To study some blood tests which would help predict severity and outcome in children with cancers having the novel corona virus infection.

Understanding the biochemical and immunological correlates of severity and outcomes of COVID-19 in children with cancer undergoing chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/05/025327
Enrollment
60
Registered
2020-05-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: D499- Neoplasm of unspecified behavior of unspecified site

Interventions

None listed

Sponsors

NO SPONSOR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All children with cancer who are undergoing treatment under Pediatric Haematology and Oncology will be included.

Exclusion criteria

Exclusion criteria: Patients who do not give consent to be included

Design outcomes

Primary

MeasureTime frame
For every child with febrile illness, the following outcomes will be measured: (1) clinical outcomes of infections (if any) including severity (pneumonia, multi-organ failure, death) and time to recover.Timepoint: Outcomes will be measured at baseline, week1, week2, week3 and at week4. Antibody response will be measured at week 4 and at 3 months.—

Secondary

MeasureTime frame
Other outcome pertaining to the malignancy which includes disease remission, progression, relapse and death will be noted if they occurred during the study frameTimepoint: during the time frame of study of 1 year—

Countries

India

Contacts

Public ContactDeepthi Boddu

Christian Medical College Vellore

drdeepthiboddu@gmail.com8056321856

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026